BIOMAT Database Logo BIOMAT Database Logo

Immunogenicity of high-titer Edmonston-Zagreb measles vaccine in human immunodeficiency virus-infected children in Kinshasa, Zaire. 1993

F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Division of Immunization, Centers for Disease Control and Prevention, Atlanta, Georgia.

The response to Edmonston-Zagreb vaccine (titer, 5.4 log10 pfu) was evaluated among children in a study of perinatal transmission of human immunodeficiency virus (HIV) in Kinshasa. Acute postvaccination adverse events were monitored for 49 HIV-infected and 376 non-HIV-infected infants, and measles antibody responses were assessed by ELISA for 34 HIV-infected and 255 non-HIV-infected infants. There was no increase in the incidence of common symptoms 7-10 days after vaccination. HIV-infected infants were more likely to have detectable prevaccination measles antibody, and seroconversion after vaccination was somewhat lower in HIV-infected (76.5%) than non-HIV-infected infants (85.5%). Seroconversion rates did not differ among children with or without rhinitis or fever at vaccination. High-titer Edmonston-Zagreb vaccine given at 6 months of age has the potential to provide earlier protection against measles; however, this vaccine is no longer recommended for routine use, and two doses of standard-titer vaccines remains the preferred option for measles vaccination of HIV-infected infants.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D008458 Measles Vaccine A live attenuated virus vaccine of chick embryo origin, used for routine immunization of children and for immunization of adolescents and adults who have not had measles or been immunized with live measles vaccine and have no serum antibodies against measles. Children are usually immunized with measles-mumps-rubella combination vaccine. (From Dorland, 28th ed) Vaccine, Measles
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015023 Democratic Republic of the Congo A republic in central Africa, east of the REPUBLIC OF THE CONGO, south of the CENTRAL AFRICAN REPUBLIC and north of ANGOLA and ZAMBIA. The capital is Kinshasa. Belgian Congo,Congo (Kinshasa),Katanga,Zaire
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Immunogenicity of Edmonston-Zagreb measles vaccine.
October 1996, Indian pediatrics,
F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Measles control in Kinshasa, Zaire improved with high coverage and use of medium titre Edmonston Zagreb vaccine at age 6 months.
June 1994, International journal of epidemiology,
F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Immunogenicity of high-titre AIK-C or Edmonston-Zagreb vaccines in 3.5-month-old infants, and of medium- or high-titre Edmonston-Zagreb vaccine in 6-month-old infants, in Kinshasa, Zaire.
November 1994, Vaccine,
F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Long term impact of high titer Edmonston-Zagreb measles vaccine on T lymphocyte subsets.
February 1994, The Pediatric infectious disease journal,
F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Antibody persistence in Gambian children after high-dose Edmonston-Zagreb measles vaccine.
October 1990, Lancet (London, England),
F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Sex differences in measles fatality and Edmonston-Zagreb measles vaccine.
August 1994, Lancet (London, England),
F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Comparison of high titer Edmonston-Zagreb, Biken-CAM and Schwarz measles vaccines in Peruvian infants.
October 1992, The Pediatric infectious disease journal,
F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Attenuation and characterisation of Edmonston-Zagreb measles virus.
January 1972, Annales immunologiae Hungaricae,
F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Immunization of young infants with Edmonston-Zagreb measles vaccine.
September 1987, The Pediatric infectious disease journal,
F T Cutts, and K Mandala, and M St Louis, and C Brown, and B Mayala, and E R Zell, and A Deforest, and M Kamenga, and F Davachi, and L E Markowitz
Safety and immunogenicity of high-dose Edmonston-Zagreb measles vaccine in children with HIV-1 infection. A cohort study in Kigali, Rwanda.
May 1992, American journal of diseases of children (1960),
Copied contents to your clipboard!